[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Xiong et al., 2021 - Google Patents

Integrins regulate stemness in solid tumor: an emerging therapeutic target

Xiong et al., 2021

View HTML @Full View
Document ID
10217964959236831890
Author
Xiong J
Yan L
Zou C
Wang K
Chen M
Xu B
Zhou Z
Zhang D
Publication year
Publication venue
Journal of Hematology & Oncology

External Links

Snippet

Integrins are the adhesion molecules and transmembrane receptors that consist of α and β subunits. After binding to extracellular matrix components, integrins trigger intracellular signaling and regulate a wide spectrum of cellular functions, including cell survival …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Xiong et al. Integrins regulate stemness in solid tumor: an emerging therapeutic target
Hamidi et al. Every step of the way: integrins in cancer progression and metastasis
Aasen et al. Connexins in cancer: bridging the gap to the clinic
Chen et al. The biology and role of CD44 in cancer progression: therapeutic implications
Valencia et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis
Martins Cavaco et al. Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis
Eke et al. Focal adhesion signaling and therapy resistance in cancer
Wang et al. Fibronectin: how its aberrant expression in tumors may improve therapeutic targeting
Detchokul et al. Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies
Conley-LaComb et al. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis
Khalili et al. A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo
Paraiso et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy–mediated metastatic melanoma phenotype
Bellahcène et al. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer
Luker et al. Functions of CXCL12 and CXCR4 in breast cancer
Tandon et al. Emerging strategies for EphA2 receptor targeting for cancer therapeutics
Cantor et al. Integrin αvβ6 sets the stage for colorectal cancer metastasis
Johnston et al. Osteopontin as a target for cancer therapy
Guo et al. Reduction of protein kinase C ζ inhibits migration and invasion of human glioblastoma cells
EA020764B1 (en) Biomarkers for inhibitors with anti-angiogenic activity
JP6921755B2 (en) Methods and Compositions to Reduce Brain Tumor Stem Cell Growth, Migration and Infiltration to Improve Survival in Brain Tumor Patients
Buraschi et al. Progranulin/EphA2 axis: A novel oncogenic mechanism in bladder cancer
Brown et al. Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology
Abdul Pari et al. Emerging paradigms in metastasis research
AU2009289136A1 (en) Materials and methods for inhibiting cancer cell invasion related to FGFR4
Andreuzzi et al. Deregulated expression of Elastin Microfibril Interfacer 2 (EMILIN2) in gastric cancer affects tumor growth and angiogenesis